samedan logo
 
 
 
spacer
home > ebr > spring 2008 > mass spectrometry for the next generation
PUBLICATIONS
European Biopharmaceutical Review

Mass Spectrometry for the Next Generation

High performance mass spectrometry advances provide powerful new research capabilities with sophisticated software solutions to biopharmaceuticals. Michael Willett of Bruker Corporation informs us of the latest developments in this cutting-edge technology

In the past year, major new developments in cutting-edge, highend mass spectrometers and mass spectrometry-based software solutions have reached research scientists in the pharmaceutical and biotechnology industries, positively impacting their research. A new generation of proteomics data warehousing, proteomics data mining and proteomics project management software is now in use by research scientists, especially in Europe. Secondly, new tools for biologics drug development have become available. In addition, mass spectrometry-based metabolic profiling is now combining complementary methods of metabolite quantitation and structure determination by nuclear magnetic resonance (NMR) with exact mass analysis by electrospray mass spectrometry (ESI-MS). Furthermore, new generations of highend mass spectrometers have now become particularly useful to pharma and biotech researchers dedicated to drug discovery and development, especially when coupled with the latest advanced solutions in MALDI molecular imaging of human and research model tissues, along with software solutions for biomarker panel discovery, identification and validation, for example.

NEW PROTEOMICS DATA WAREHOUSING AND PROJECT MANAGEMENT SOFTWARE PRODUCE POSITIVE PROTEIN RESEARCH RESULTS

With a new generation of proteomics data warehousing software now in use, next-generation bioinformatics platforms addressing scientists’ current needs in proteomics identification and biomarker profiling, quantification and validation have become available. As a comprehensive solution for qualitative and quantitative liquid chromatography (LC)-MS/MS protein analysis, such proteomics software can now support all current label chemistries including multiplexed labels, as well as label-free quantification. Interactive validation of protein quantification based on raw LC/MS data has become simple and straightforward, streamlining the discovery process through decoy auto-validation algorithms and algorithms that produce non-redundant protein result lists across entire proteomics projects, including brain proteomics projects.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Michael Willett has been the Public relations and Investor Relations Officer of Bruker Corporation since September 2002, and was the Investor Relations Director at Bruker Daltonics from 2000 to 2002. Prior to joining Bruker Daltonics, Michael was the International Finance, Tax and Accounting Manager at a leading healthcare policy consulting firm from 1998 to 2000. Previously, he was IR Director at a computer company for five years. Early in his career, Michael was an Audit Manager with Ernst & Young LLP in New York, Barcelona and Zurich. A CPA, he holds a BA and a BSE from the University of Connecticut, and an MBA from Columbia University, followed by post-MBA study at Northwestern University in Chicago.
spacer
Michael Willett
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PharmaFluidics awarded VLAIO research grant

Ghent, Belgium – June 2, 2020 PharmaFluidics NV, innovative player in the field of analytical chromatography with its unique high-resolution µPAC™ micro-Chip technology, announces that it has been awarded a € 613 k grant from Flanders’ Innovation & Entrepreneurship Agency (VLAIO). The grant will run over two years and will support the further optimization of PharmaFluidics’ manufacturing flow, and to develop complementary new surface-modified µPAC™ products.
More info >>

White Papers

Microalgae Culture Using the DASGIP® PBR4 Module for Illumination with a New Brunswick™ CelliGen® 310 Stirred-tank Bioreactor

Eppendorf

The number of bioprocess applications for microalgae has increased in recent years, particularly in the fi eld of biofuel production. The combination of the New Brunswick CelliGen 310 stirred-tank bioreactor and the DASGIP LED Illumination System creates a bioreactor setup which is capable of supporting high density microalgal growth. Using the stand-alone Eppendorf DASGIP PBR4 Module, LED illumination spectra and intensities can be controlled for optimal support of all types of chlorophylls and carotenoids. For this study in which high density culture of up to 1.5 x 107 cells/mL was achieved, the unicellular freshwater alga, Dunaliella tertiolecta, was used.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement